University Hospital of Toulouse
Welcome,         Profile    Billing    Logout  
 163 Trials 
41 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hitzel, Anne
NCT04265209 / 2019-000247-27: [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Recruiting
3
152
Europe
SPECT, PET
Zionexa
Parkinson Disease, Essential Tremor
09/24
12/24
PLAT, Geneviève
CAALL-F01, NCT02716233: A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents

Recruiting
3
1578
Europe
pegaspargase 1250 IU/m2 x 2, ONCASPAR 1250 IU/m2 x 2, pegaspargase 2500 IU/m2 x 1, ONCASPAR 2500 IU/m2 x 1
Assistance Publique - Hôpitaux de Paris, Shire
Acute Lymphoblastic Leukemia
04/26
04/26
Gourdy, Pierre
SURPASS-SWITCH, NCT05564039: A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide

Completed
4
282
Europe, US, RoW
Tirzepatide, LY3298176, Dulaglutide, LY2189265
Eli Lilly and Company
Type 2 Diabetes
07/24
08/24
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
SP12, NCT04749693: Observational Study of the Use of DBLG1 System in Real Life

Recruiting
N/A
348
Europe
DBLG1 System
Diabeloop
Type1diabetes
07/25
01/26
Sailler, Laurent
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Terminated
2
85
Europe, US, RoW
LY3361237, Placebo
Eli Lilly and Company
Systemic Lupus Erythematosus
12/23
12/23
BUREAU, Christophe
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Completed
3
160
Europe
Rifaximin, Placebo
Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA
Cirrhosis, Ascites, Peritonitis
06/22
03/23
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
DHELIVER, NCT04229901: Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)

Terminated
2
133
Europe, RoW
HepaStem, Placebo
Cellaion SA
Acute on Chronic Liver Failure
05/24
05/24
FRESH, NCT05639543 / 2022-001639-10: FXR Effect on Severe Alcohol-Associated Hepatitis () Study

Recruiting
2
50
Europe, US
INT-787, Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Alcohol Associated Hepatitis
12/24
03/25
MAURY, Philippe
NCT03737929: Hybrid Therapy and Heart Team for Atrial Fibrillation

Recruiting
N/A
228
Europe
Hybrid ablation, Percutaneous catheter ablation
University Hospital, Toulouse, AtriCure, Inc.
Atrial Fibrillation
12/25
12/25
OUSSET, Pierre-Jean
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Recruiting
2
282
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
12/26
02/29
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
Delrieu, Julien
LIGHT4LIFE, NCT05926011: Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease

Recruiting
N/A
108
Europe
RGn600, RGn600 Sham
REGEnLIFE SAS, RCTs, University Hospital, Toulouse
Alzheimer Disease
05/25
12/25
Huart, Antoine
EMN22, NCT04131309 / 2018-004333-33: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Active, not recruiting
2
40
Europe
Daratumumab, Bortezomib Injection, velcade, Dexamethasone oral tablet
Stichting European Myeloma Network, Janssen Pharmaceutica
Light Chain (AL) Amyloidosis, Stage 3B
01/25
01/25
IsAMYP, NCT05066607: Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy

Recruiting
2
46
Europe
Isatuximab, Pomalidomide, Dexamethasone
Intergroupe Francophone du Myelome, Sanofi, Bristol-Myers Squibb
AL Amyloidosis
03/26
03/26
VALTON, Luc
GALVANI GS-3, NCT06334952: Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic

Recruiting
N/A
60
Europe
transcranial direct current stimulation, Research MRI, EEG
Assistance Publique Hopitaux De Marseille, CRMBM-CEMEREM, Institut National de la Santé Et de la Recherche Médicale, France - LTSI, Neuroelectrics Corporation
Epilepsy, Drug Resistant Epilepsy
12/26
11/27
WOISARD, Virginie
Eph-L, NCT06014710: Modelling of Pharyngeal Laryngeal Effectiveness

Recruiting
N/A
520
Europe
Swallowing evaluation
University Hospital, Toulouse, National Research Agency, France, Institut de Recherche en Informatique de Toulouse (IRIT), Laboratoire parole et langage, Swallis Medical
Swallowing Disorders
12/24
06/25
RITZ, Patrick
PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Recruiting
2
72
Europe, US
Pasireotide Diaspartate, Pasireotide
RECORDATI GROUP
Post-Bariatric Hypoglycemia
04/25
04/26
PASQUET, Marlène
ALLTogether1, NCT04307576 / 2018-001795-38: A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting
3
6430
Europe, RoW
Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Besponsa+Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab, Blincyto
Mats Heyman, The Swedish Research Council, The Swedish Childhood Cancer Foundation, Pfizer, Servier, NordForsk, Aamu Pediatric Cancer Foundation, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Clinical Trial Center North (CTC North GmbH & Co. KG), Belgium Health Care Knowledge Centre, Karolinska Institutet, Cancer Research UK, Fundação Rui Osório de Castro, Acreditar - Associação de Pais e Amigos das Crianças com Cancro, Grupo Português De Leucemias Pediátricas, Amgen, Nova Laboratories Limited, Danish Child Cancer Foundation, Danish Cancer Society, The Novo Nordic Foundation, Assistance Publique - Hôpitaux de Paris, Direction Générale de l'Offre de Soins
Leukemia, Acute Lymphoblastic
06/27
06/32
Guibert, Nicolas
NCT04517916: Zephyr Etude Post-Inscription (French Registry)

Active, not recruiting
N/A
155
Europe
Zephyr Valve, Zephyr System, BLVR
Pulmonx Corporation
Emphysema or COPD
06/22
09/25
CONVERT, NCT04559464: Fissure Closure With the AeriSeal System for ing Collateral Ventilation Status

Completed
N/A
102
Europe, RoW
AeriSeal, Zephyr Valves, Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System
Pulmonx Corporation
Emphysema, COPD, Severe Emphysema
10/23
10/24
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema

Recruiting
N/A
200
Europe, US, RoW
AeriSeal System
Pulmonx Corporation
Emphysema, Pulmonary, Emphysema or COPD
06/27
03/28
AIRFLOW-3, NCT03639051: Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Active, not recruiting
N/A
464
Europe, US
Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care
Nuvaira, Inc.
COPD
10/24
09/28
French TARGET, NCT05118269: A Randomized Controlled Trial of InterVapor® in France - The TARGET Trial

Not yet recruiting
N/A
150
NA
Treatment plus Optimal Medical Therapy, InterVapor, BTVA, Optimal Medical Therapy
Uptake Medical Technology, Inc., MedPass International
Emphysema
07/25
07/26
SULTAN, Ariane
SURPASS-SWITCH, NCT05564039: A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide

Completed
4
282
Europe, US, RoW
Tirzepatide, LY3298176, Dulaglutide, LY2189265
Eli Lilly and Company
Type 2 Diabetes
07/24
08/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
BOUNES, Fanny
NCT05156983 / 2021-004138-12: A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Recruiting
3
328
Europe, Canada, US
TAK-330, SOC 4F-PCC
Takeda, Takeda Development Center Americas, Inc.
Coagulation Disorder
04/28
04/28
Mazereeuw-Hautier, Juliette
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
02/26
02/27
VITANI, NCT05917561: Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

Recruiting
2
48
Europe
Anifrolumab Infusion Product, Placebo
University Hospital, Bordeaux, AstraZeneca
Vitiligo
05/26
05/26
PelBurd, NCT05588310: Quantification of the Socio-economic Multifacet Burden of Alopecia Areata and Identification of the Associated Factors

Recruiting
N/A
150
Europe
University Hospital, Toulouse, Pfizer
Alopecia Areata
04/25
04/25
Faguer, Stanislas
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Recruiting
3
160
Europe, Canada, Japan, US, RoW
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
GlaxoSmithKline
Eosinophilic Granulomatosis With Polyangiitis
10/25
11/25
GUY, Laurent
ALBAN, NCT03799835 / 2017-004512-19: Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Active, not recruiting
3
517
Europe
BCG, Bacillus Calmette Guerin (BCG) Medac®, OncoTice, Atezolizumab, MPDL3280A, Tecentriq®
UNICANCER, Hoffmann-La Roche
Bladder Cancer
06/25
10/28
NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting
3
112
Europe, US
ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Fidia Farmaceutici s.p.a.
Bladder Carcinoma in Situ (CIS)
11/25
11/27
Cintas, Pascal
NCT05508074 / 2021-003875-32: Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)

Active, not recruiting
2
51
Europe
IFB-088 50mg/day, IFB-088, Icerguastat, Placebo, Riluzole 100mg/day, Riluzole
InFlectis BioScience, InFlectis BioScience,
Amyotrophic Lateral Sclerosis, ALS
01/25
01/25
RNALS, NCT05928416: ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach

Recruiting
N/A
600
Europe
Saliva sample
ZIWIG, Monitoring Force Group
Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic Lateral Sclerosis
07/25
07/25
Jouret, Beatrice
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
WOISARD, MD
Eph-L, NCT06014710: Modelling of Pharyngeal Laryngeal Effectiveness

Recruiting
N/A
520
Europe
Swallowing evaluation
University Hospital, Toulouse, National Research Agency, France, Institut de Recherche en Informatique de Toulouse (IRIT), Laboratoire parole et langage, Swallis Medical
Swallowing Disorders
12/24
06/25
BROCHARD-PAYET, Karine
No trials found
BUFFIERES, William
No trials found
ROUBLIN, Clemence
No trials found
CHAUBE, Johanna
No trials found
ALGANS, Nadege
No trials found
PUEL, Floriane
No trials found

Download Options